JAK1/TYK2-selective dual kinase inhibitor

oral activity in arthritis model

from SBDD of prior internal matter

Bioorg. Med. Chem. Lett., Mar. 31, 2020

Pfizer, Cambridge, MA and Groton, CT

Compound 19

“Compound 19” is a JAK1/TYK2 dual kinase inhibitor from Pfizer, related to its clinical JAK1/TYK2 dual inhibitor, brepocitinib, in Ph. II for a variety of inflammatory diseases. The cyclopropyl amide…

get free samples and a Premium trial

Premium members get access to our library of hundreds of in-depth reviews on key molecules, ten new reviews each month, novel drug approval coverage, drug discovery company updates, and more: